Changing course: SignalPath aims to reimagine research, accelerate tech-enabled clinical trials

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ipopba)
(Image: Getty/ipopba)

Related tags: Technical support, Research, Real world evidence, Real world data, Oncology, Clinical trials, Design

SignalPath is creating a research consortium through which it aims to leverage real world data to redesign clinical trials.

SignalPath, a health care technology and services company specializing in clinical research, has created the SignalPath Research Consortium, to bring together technology companies, life science sponsors, and research sites.

Brad Hirsch, CEO of SignalPath told us that the partnerships gained through the network will allow for the reimagining of clinical trials, powered by the technology that the sites use daily.

“While our technology at sites provides the foundation to support key functions like finance, operations, and startup, the need is broader. So we are working to bring our sites together through elements like education, community forums, and new trial opportunities,”​ said Hirsch

Companies like Florence Healthcare and Genentech will be joining forces with SignalPath to strengthen the consortium, which will include a network of clinical trial sites connected through a technical foundation.

The consortium will connect sites, sponsors, and research companies that will employ the software and data necessary for the development of oncology treatments more efficiently and affordable.

Hirsch told us, “Our goal is to grow the consortium in terms of sites and partners in order to reimagine the clinical trials that can be deployed across the ecosystem.”

By 2020, the company expects that it will be offering clinical trials that leverage real world experience in conjunction with its network sites, partners, and sponsors, said Hirsch.

SignalPath also will be working with the Biden Cancer initiative as a preview of how the consortium will deliver on the goals it has set. Hirsch said, “They [Biden Cancer Initiative] have been very helpful in bringing the group together and pushing to shrink timelines and drive productivity.”

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more